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Abstract
Objective—We compared three ad hoc methods to estimate the marginal hazard of incident cancer
AIDS in a highly active antiretroviral therapy (1996–2006) relative to a monotherapy/combination
therapy (1990–1996) calendar period, accounting for other AIDS events and deaths as competing
risks.
Study Design and Setting—Among 1911 HIV+ men from the Multicenter AIDS Cohort Study,
228 developed cancer AIDS and 745 developed competing risks in 14,202 person-years from 1990–
2006. Method 1 censored competing risks at the time they occurred, method 2 excluded competing
risks, and method 3 censored competing risks at the date of analysis.
Results—The age, race and infection duration adjusted hazard ratios (HRs) for cancer AIDS were
similar for all methods (HR≅0.15). We estimated bias and CI coverage of each method with Monte
Carlo simulation. On average across 24 scenarios, method 1 produced less biased estimates than
methods 2 or 3.
Conclusions—When competing risks are independent of the event of interest, only method 1
produced unbiased estimates of the marginal HR, though independence cannot be verified from the
data. When competing risks are dependent, method 1 generally produced the least biased estimates
of the marginal HR for the scenarios explored; however, alternative methods may be preferred.
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• While it is not possible to learn whether competing risks are dependent or
independent from observed data, when competing risks are independent, censoring
competing risks at the time that they occur produces unbiased estimates of the
marginal hazard ratio, while excluding competing risks, or censoring at the date
of analysis may bias results.
• When competing risks are dependent, censoring competing risks produced
estimates of the marginal hazard that were less biased than those produced by
excluding competing risks or censoring at the date of analysis. However, more
formal competing risks methods may be preferred.
What this adds to what was known
• This paper highlights the use of informal competing risks methods that may be
used by epidemiologists with the intention of estimating the marginal hazard ratio;
and demonstrates when each method may be biased.
What is the implication?
• When epidemiologists are interested in estimating the marginal hazard ratio and
have dependent competing risks, using the “ad hoc” methods presented here may
induce bias, and more formal methods may be needed.
When estimating the effect of highly active antiretroviral therapy (HAART) on incident AIDS-
defining cancers, often only the initial AIDS diagnosis is available or of interest, and other
AIDS-defining events (e.g., opportunistic infections) and deaths are considered to be
competing risks. “Formal” methods that account for competing risks, such as regression for
cumulative incidence functions [1] or mixture models [2], are rarely used by epidemiologists.
Of the over 700 original contributions that appeared in the Journal of Clinical Epidemiology,
American Journal of Epidemiology, Epidemiology and the International Journal of
Epidemiology in 2007, only three [3-5] used competing risks methods. When competing risks
methods are used, the specific type of hazard ratio (HR) that is sought (i.e., the estimand) is
often not clearly stated. For example, one may wish to estimate the ratio of the marginal hazards,
the cause-specific hazards or the hazards of the subdistribution. Though these estimands are
superficially similar, they are fundamentally different. We posit that epidemiologists
conducting etiologic research are often interested in estimating the effect of exposure on the
latent time to the event of interest, or the marginal hazards. Once the estimand is stated, there
are often competing estimators. For example, when studying the effect of HAART on specific
types of AIDS events, epidemiologists have: (i) censored individuals who incur a competing
risk at the time of the competing risk [6], (ii) excluded individuals who incur a competing risk
[7], or (iii) censored individuals who incur a competing risk at the date of analysis [8]. When
the ratio of the marginal hazards is the desired estimand and the methods described above are
used, they can be considered ad hoc methods for estimating the ratio of the marginal hazards.
It is unclear whether any or all of these ad hoc methods produce unbiased estimates of the
marginal HR with appropriate confidence interval (CI) coverage. Below, we assessed the effect
of HAART on AIDS-defining cancers using these three ad hoc methods to account for incident
non-cancer AIDS and AIDS-free death as competing risks with observational data from the
Multicenter AIDS Cohort Study. We also assessed the possible bias and CI coverage for these
three ad hoc methods using Monte Carlo simulation.
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Since 1984, the Multicenter AIDS Cohort Study (MACS) has enrolled 6,972 homosexual and
bisexual men in Baltimore, MD, Chicago, IL, Pittsburgh, PA, and Los Angeles, CA to study
the natural and treated histories of HIV infection [9]. MACS participants complete semiannual
physical examinations and questionnaires that include information on medication and
treatments, and provide blood for laboratory measurements, including CD4 cell count.
This analysis included 1,911 men, 493 who seroconverted with HIV while under observation
with dates of seroconversion known to within two years and 1,418 who were HIV seroprevalent
at the time of enrollment. The MACS participants not included in this analysis were HIV-
negative, and therefore were not at risk for AIDS,or had already developed AIDS, died or were
lost to follow-up prior to 1990. MACS obtained institutional review board approval from
participating institutions and all participants provided written informed consent.
Endpoint ascertainment
The outcome of interest was an incident (i.e., presenting) AIDS-defining cancer, either
Kaposi’s sarcoma or non-Hodgkin lymphoma. All other incident AIDS-defining events,
including opportunistic infection, wasting syndrome, HIV-associated dementia and AIDS-free
deaths were considered to be competing risks. Subsequent AIDS diagnoses that occurred after
the presenting AIDS diagnoses were not considered to be events in this analysis. Clinical AIDS
events were ascertained through participant self-report, and verified by medical record
abstraction. Clinical AIDS was defined according to the 1993 Centers for Disease Control and
Prevention criteria [10]. Individuals with only an immunologically-defined AIDS event (CD4
count <200 cells/μl or CD4% <14%) were not considered to have a clinical AIDS-defining
illness for this analysis. Date of death was obtained through active and passive searches of
death records and through the National Death Index.
Exposure assessment
Antiretroviral therapy exposure was assessed using calendar period as an instrument for
HAART [11-23] to avoid the confounding that occurs when individual-level antiretroviral
therapy use is used as exposure [13,16,24]. Calendar period meets the criteria of an instrument
[25], because calendar period is (i) associated with antiretroviral therapy; (ii) independent of
known confounders of the relationship between antiretroviral therapy and AIDS-free time; and
(iii) independent of AIDS-free time, conditional on antiretroviral therapy [13,26]. Person-time
was partitioned into the following calendar periods: monotherapy/combination therapy (1
January 1990–31 December 1995) and HAART (≥1 January 1996).
Statistical analysis
Seroconversion date—Among seroincident men, we defined seroconversion as one-third
the time between the last negative and the first positive visits (median seroconversion window:
0.52 years; interquartile range (IQR): 0.48, 0.59). Among seroprevalent men, we imputed the
unknown date of seroconversion 20 times. Imputations were drawn from a log-normal model
for time from seroconversion to a given semiannual study visit conditional on age, type of
event, CD4 cell count, race, and time from visit to event or censoring. Type of event (cancer
AIDS/non-cancer AIDS/AIDS-free) and race (white/non-white) were treated as categorical
variables. Age, CD4 cell count and time from visit to event or censoring were modeled as
restricted cubic splines with knots at the 5th, 50th and 95th percentiles [27]. Multiple imputations
were combined using Rubin’s method [28]. The earliest imputed seroconversion date was May
1978, and the distribution of imputed seroconversion dates reflected the known dynamics of
Shiels et al. Page 3













the HIV epidemic in the United States. The peak of HIV incidence in our study was 1983,
consistent with a recent United States estimate of a peak between 1984 and 1985 [29].
Estimating dates of seroconversion was necessary, because infection duration was an important
confounder in our analysis.
Data analysis—Person-time accrued for each participant from the latter of date of
seroconversion (imputed in seroprevalent men), date of study entry or 1 January 1990 until the
first of incident AIDS, death, loss to follow-up, or administrative censoring on 31 December
2006. HRs for AIDS-defining cancers and 95% confidence intervals (CI) were estimated with
Cox proportional hazards regression [30], accounting for competing risks using the three
methods described below. HRs for AIDS-defining cancers were estimated for the HAART
calendar period, compared to the monotherapy/combination therapy calendar period. To
control for confounding, the regression models were weighted by the inverse probability-of-
exposure [31,32]. Weights were calculated using a logistic model, conditional on age at
seroconversion, infection duration and race. Age at seroconversion and infection duration were
modeled as restricted cubic splines with knots at the 5th, 50th and 95th percentiles, to allow
non-linear associations with calendar period [27]. Race (white/non-white) was modeled as an
indicator variable. We used generalized estimating equations with an independent covariance
structure to produce robust variance estimates to account for the weights. Data was analyzed
with SAS version 9.1 (SAS Institute, Cary, NC).
Competing risk methods—Competing risks occur when there is more than one type of
outcome, and experiencing one type of outcome precludes the other type of outcome from
occurring or being observed. For example, experiencing a first AIDS-diagnosis of non-cancer
AIDS precludes a participant from experiencing a first AIDS-diagnosis of cancer AIDS. Three
ad hoc methods were employed here.
Method 1, the “censor method,” estimates the cause-specific hazard, the probability of failure
due to the event of interest, given that no failure of any type previously occurred [33-36]. When
a single event type is of interest, method 1 censors each competing risk at the time at which it
occurs, as shown in figure 1 panel B. Specifically, figure 1, panel A shows observed data for
five individuals. Subject 1 has a competing risk at year 5, subject 2 has an event of interest at
year 4, subject 3 has an event of interest at year 1, subject 4 has a competing risk at year 2, and
subject 5 is censored at year 6. Figure 1, panel B shows implementation of method 1, where
the competing risk of subject 1 and subject 4 are censored at the time of the competing risk.
Method 1 is probably the most commonly employed method to handle competing risks
[35-38]. Many investigators censor competing deaths during survival analysis, implementing
method 1 without acknowledging this technique as a competing risks method. Additionally,
investigators generally do not state the specific type of HR that they wish to estimate when
using method 1; method 1 produces a cause-specific HR.
Method 2, the “exclude method,” excludes all competing risks from the data set [7], as shown
in figure 1 panel C. Specifically, in figure 1 panel C, data from subjects 1 and 4 are excluded
from analysis. Thus, those who developed a first non-cancer AIDS event or who died prior to
developing an AIDS event were excluded from the data prior to carrying out analysis. Method
2 produces an estimate of a conditional HR, where the HR applies to a subset of those who
will incur the event of interest.
Method 3, the “extend method,” extends the person-time to the date of analysis and then censors
all competing risks [8,39,40], as shown in figure 1 panel D. Specifically, in figure 1 panel D,
subjects 1 and 4 have their time at risk extended until 6 years. Thus, in our analysis, those who
developed a first non-cancer AIDS event or who died prior to developing an AIDS event were
censored at 31 December 2006. Method 3 produces an estimate of the subdistribution HR, the
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probability of failing due to the event of interest given the absence of a previous failure due to
the event of interest or the presence of a previous failure due to another event type [41].
However, without the inverse probability-of-censoring weights described by Fine and Gray
[1]; method 3 does not necessarily provide a consistent estimator of the subdistribution HR.
Monte Carlo simulation—To compare the estimates and CI coverage of each ad hoc
method, data were simulated for 24 scenarios [42]. Assuming that 1/3 of the subjects were
exposed, 2,000 datasets of 500 subjects were simulated for each combination of the following
parameters: an HR of the event of interest of 1 or 2; an HR of the competing event of 1, 1/2 or
2; 20% or 50% administrative censoring; and independent or dependent competing risks. Event
and competing risk times were drawn from similar Weibull distributions with a common
subject-specific normally-distributed frailty, and the earlier of the two times was assigned as
the observed outcome. We take the true HR to be the ratio of the marginal hazards. To
approximate the integration over the distribution of the frailty and obtain the marginal hazards
we used the Kullback-Leibler information criteria [43] estimated on a sample of 1 million
subjects weighted by the inverse probability-of-exposure given the frailty. An administrative
censoring time was chosen to control the proportion administratively censored at 20% or 50%.
The antilog of the absolute value of the difference between the log of the true HR and the mean
log HR was used as a measure of bias. The mean standard error of log HR and the standard
deviation of the log HR were used as measures of precision. The proportion of 95% CIs that
included the true HR was used as a measure of the CI coverage. Simulation results are subject
to Monte Carlo error; based on the 2,000 simulations, the 95% CI coverage estimates have a
simulation standard error of ± 1/2%.
RESULTS
From 1 January 1990 to 31 December 2006, 745 clinical AIDS-defining events were diagnosed
among 1911 men during 14 202 person-years of follow-up. Of the incident AIDS events, 228
were AIDS-defining cancers (175 Kaposi’s sarcoma, 42 non-Hodgkin lymphoma and 11
central nervous system lymphomas). The 616 other AIDS-defining illnesses consisted
predominantly of opportunistic infections (n=503), but also included wasting syndrome (n=83)
and HIV-related dementia (n=30). An additional 129 men died without AIDS.
Seventy-seven percent of the men were white/non-Hispanic. The median date of
seroconversion, age at seroconversion, and years of follow-up time from seroconversion to
AIDS or censoring were August 1983 (IQR=September 1982, March 1986), 31 years old
(IQR=26, 36), and 5.1 years (IQR=2.3, 14.4), respectively. On average, seroprevalent men had
an earlier imputed median date of seroconversion, a younger median age at seroconversion, a
shorter follow-up, a smaller proportion of white/non-Hispanic men, and a greater proportion
of AIDS-defining events than seroincident men (table 1).
When the HAART calendar period was compared to the monotherapy/combination therapy
calendar period, the HRs were similar for all three ad hoc methods. Method 1 (HR=0.164; 95%
CI: 0.079, 0.340), method 2 (HR=0.127; 95% CI: 0.079, 0.203), and method 3 (HR=0.146;
95% CI: 0.071, 0.299) showed HRs ≅ 0.15 for incident cancer AIDS in the HAART era (table
2). No meaningful difference in the estimates was seen when the inverse-probability-of-
exposure weights were truncated at the 1st and 99th percentile.
Appendix 1 shows a summary of the results of the simulation study conducted under 24
scenarios. When the events were dependent, the data were simulated with a correlation of 0.2
to 0.3 between events and competing risks. When the competing risks were independent,
method 1 (the “censor method”) produced valid estimates of the marginal HR, regardless of
the HR of the association between the exposure and the event of interest, the HR of the
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association between the exposure and the competing event or the proportion of participants
censored. Methods 2 and 3 were only valid in 3 out of 12 scenarios under independent
competing risks. When the competing risks were dependent, all three ad hoc methods produced
relatively unbiased estimates only when the HR and competing risks HR were both null. In
general, when the competing risks HR=1/2, method 2 (the “exclude method”) underestimated
the true marginal HR and method 3 (the “extend method”) overestimated the true marginal
HR, and when the competing risks HR=2, method 2 overestimated the true marginal HR and
method 3 underestimated the true marginal HR. Additionally, the bias was greater in the
presence of 20% censoring than 50% censoring. The precision of each method was
approximately equal in each scenario.
In 24 scenarios, the estimates produced by method 1 (the “censor method”) were generally less
biased than those produced by methods 2 or 3. On average across all scenarios, the absolute
relative bias for method 1 was 1.03, whereas the absolute relative bias for method 2 was 1.11
and the absolute relative bias for method 3 was 1.13 (table 3). 95% of 95% CIs included the
true marginal HR when method 1 was applied, 88% of 95% CIs included the true HR when
method 2 was applied and 83% of 95% CIs included the true marginal HR when method 3 was
applied.
DISCUSSION
Three ad hoc methods for addressing competing risks produced similar HRs when estimating
the effect of HAART on incident cancer AIDS, accounting for incident non-cancer AIDS and
deaths as competing risks. Each method showed a reduction of approximately 85% in AIDS-
defining cancers in the HAART era when compared to the monotherapy/combination therapy
era.
Using Monte Carlo simulation, we compared the estimates of the marginal HR produced by
each ad hoc method under 24 scenarios varying the HR of the event of interest, the HR of the
competing risk, proportion censored and dependence of competing risks. When the true HR of
the event of interest and the HR of the competing risk were both 1, regardless of the proportion
censored or the dependence of events, each ad hoc method produced unbiased estimates.
Overall, estimates were more biased when the HR of the competing risk was non-null and in
the presence of light censoring (i.e. many competing events). The amount of data that is altered
under ad hoc methods 2 and 3 (i.e., the number of participants that are either excluded in method
2 or have their person-time extended until date of analysis in method 3) is a function of the
proportion of competing risks. Therefore, it is intuitive that studies with a large proportion of
competing risks would produce more biased results.
The inferences that we are able to draw from our simulations are limited by examining the
performance of each method in only 24 out of many possible scenarios. Future studies may
wish to additionally alter the proportion exposed, the ratio of competing risks to events, the
strength of the dependence between competing risks and events, and the effect of covariates.
While investigators usually state that they are estimating the HR [7,8,36], it is usually not noted
that method 1 estimates the cause-specific HR, method 2 estimates a conditional HR, and
method 3 approximates the subdistribution HR. Our simulations take the marginal HR on the
latent time to the event of interest as the true HR; the cause-specific HR is equivalent to the
marginal HR in the case of independence [36,44].
Each ad hoc method addresses competing risks imperfectly, though epidemiologists have used
each of these methods in past to address competing risks when estimating the effect of HAART
on specific types of AIDS events [6-8]. When competing risks are independent, and method 1
is utilized, the survival experience of uncensored observations represents the unobserved
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survival experience of the competing risks. Thus, this method is only a valid estimate of the
marginal HR when the event of interest and the competing risk are independent, given
covariates included in the regression model. In observed data it is not possible to assess the
dependence between the event of interest and the competing risk [45]. However, the
independence assumption can be relaxed to depend on a larger set of covariates by the use of
inverse probability-of-censoring weights [46,47]. Methods 2 and 3 take different approaches
to circumvent the biases associated with method 1 when the events are dependent. However,
by excluding competing risks or extending competing risks to the date of analysis, the person-
time at risk could be greatly under- or over-estimated. This may be of particular concern if the
alteration in person-time is differential by exposure category. Finally, in all three methods,
losses to follow-up are only redistributed to become events of interest, and not competing risks.
This may induce bias when a study has a high rate of attrition.
Our results suggest that use of these ad hoc methods to estimate the marginal HR should be
circumscribed. Though independence cannot be determined from the data, when the competing
risks are thought to be independent of the event of interest, method 1 (the “censor method”)
may be used, as it produces unbiased estimates of both the marginal and cause-specific HRs.
Second, when the competing risks are dependent, models for the cumulative incidence function
[1] or mixture models [2,48] may be preferred; perhaps at the cost of altering the estimand. In
the absence of such formal methods, method 1 (the “censor method” or a model for the cause-
specific hazard) appears to be preferred over ad hoc methods 2 or 3 as estimates of the marginal
HR. As epidemiologists rarely use competing risks methods, or identify the type of estimand
that they are estimating when competing risks are present, there is a need for future work on
applying competing risks in the epidemiologic literature.
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Appendix 1. Monte Carlo simulation results applying 3 ad hoc competing
risks methods under 24 scenarios, varying the HR, the competing risks HR,
the proportion censored and both independent (panel A) and dependent
(panel B) competing risks
A. Independent Competing Risks








1 Competing Risk HR=1 Method 1 1.01 0.191 0.190 96%
Method 2 1.01 0.191 0.188 95%
Method 3 1.00 0.191 0.197 95%
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A. Independent Competing Risks





2 Competing Risk HR=0.5 Method 1 1.01 0.179 0.166 97%
Method 2 1.09 0.179 0.166 96%
Method 3 1.10 0.179 0.167 91%
3 Competing Risk HR=2 Method 1 1.01 0.210 0.201 97%
Method 2 1.17 0.210 0.204 86%
Method 3 1.15 0.210 0.201 93%
20% censoring
4 Competing Risk HR=1 Method 1 1.01 0.150 0.163 94%
Method 2 1.00 0.150 0.161 96%
Method 3 1.01 0.150 0.162 92%
5 Competing Risk HR=0.5 Method 1 1.01 0.140 0.128 97%
Method 2 1.22 0.140 0.131 77%
Method 3 1.22 0.140 0.129 71%
6 Competing Risk HR=2 Method 1 1.03 0.171 0.162 97%
Method 2 1.35 0.171 0.170 60%




7 Competing Risk HR=1 Method 1 1.01 0.169 0.161 96%
Method 2 1.01 0.169 0.159 97%
Method 3 1.01 0.169 0.162 96%
8 Competing Risk HR=0.5 Method 1 1.01 0.163 0.169 94%
Method 2 1.09 0.163 0.170 92%
Method 3 1.08 0.163 0.170 95%
9 Competing Risk HR=2 Method 1 1.02 0.182 0.175 96%
Method 2 1.14 0.181 0.171 90%
Method 3 1.14 0.181 0.179 92%
20% censoring
10 Competing Risk HR=1 Method 1 1.00 0.136 0.138 94%
Method 2 1.08 0.136 0.145 91%
Method 3 1.07 0.136 0.135 92%
11 Competing Risk HR=0.5 Method 1 1.01 0.129 0.127 96%
Method 2 1.22 0.130 0.127 67%
Method 3 1.14 0.127 0.130 85%
12 Competing Risk HR=2 Method 1 1.01 0.148 0.163 94%
Method 2 1.21 0.148 0.154 73%
Method 3 1.40 0.146 0.158 36%
B. Dependent Competing Risks
Shiels et al. Page 8













A. Independent Competing Risks








13 Competing Risk HR=1 Method 1 1.00 0.101 0.184 97%
Method 2 1.01 0.191 0.189 96%
Method 3 1.00 0.191 0.183 97%
14 Competing Risk HR=0.5 Method 1 1.01 0.180 0.189 93%
Method 2 1.08 0.180 0.189 95%
Method 3 1.11 0.180 0.187 90%
15 Competing Risk HR=2 Method 1 1.05 0.212 0.204 97%
Method 2 1.09 0.211 0.203 95%
Method 3 1.19 0.211 0.209 89%
20% censoring
16 Competing Risk HR=1 Method 1 1.00 0.151 0.149 96%
Method 2 1.00 0.151 0.156 95%
Method 3 1.00 0.151 0.146 95%
17 Competing Risk HR=0.5 Method 1 1.07 0.139 0.139 91%
Method 2 1.08 0.139 0.145 87%
Method 3 1.28 0.139 0.135 55%
18 Competing Risk HR=2 Method 1 1.08 0.170 0.174 93%
Method 2 1.09 0.170 0.177 80%




19 Competing Risk HR=1 Method 1 1.01 0.170 0.190 94%
Method 2 1.02 0.170 0.193 96%
Method 3 1.00 0.170 0.188 94%
20 Competing Risk HR=0.5 Method 1 1.01 0.163 0.168 96%
Method 2 1.08 0.163 0.166 93%
Method 3 1.08 0.163 0.168 92%
21 Competing Risk HR=2 Method 1 1.02 0.184 0.183 95%
Method 2 1.07 0.183 0.186 92%
Method 3 1.17 0.183 0.181 88%
20% censoring
22 Competing Risk HR=1 Method 1 1.02 0.136 0.133 94%
Method 2 1.08 0.136 0.132 93%
Method 3 1.01 0.135 0.138 95%
23 Competing Risk HR=0.5 Method 1 1.02 0.136 0.133 93%
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A. Independent Competing Risks





Method 2 1.23 0.130 0.132 68%
Method 3 1.15 0.130 0.136 81%
24 Competing Risk HR=2 Method 1 1.01 0.148 0.153 96%
Method 2 1.12 0.148 0.160 93%
Method 3 1.32 0.147 0.151 56%
Glossary
AIDS Acquired Immune Deficiency Syndrome
CI confidence interval
HAART highly active antiretroviral therapy
HIV Human Immunodeficiency Virus
HR hazard ratio
MACS Multicenter AIDS Cohort Study
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Description of Four Ad Hoc Competing Risks Methods
Panel A: data for 5 individuals.
Panel B (method 1): the competing risk of subject 1 and subject 4 are censored at the time of
the competing risk.
Panel C (method 2): data from subjects 1 and 4 are excluded from analysis.
Panel D (method 3): subjects 1 and 4 have their time at risk extended until 6 years
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Table 1
Descriptive Characteristics of Seroincident and Seroprevalent Men in the Multicenter AIDS Cohort Study
Seroincident Seroprevalent Total
N 493 1418 1911
Baseline visit date 1984.8 (1984.6, 1985.1) 1984.8 (1984.6, 1985.1) 1984.8 (1984.6, 1985.1)
Date of seroconversion*†‡ 1988.0 (1985.5, 1992.1) 1983.1 (1982.4, 1985.0) 1983.6 (1982.7, 1986.2)
Age at seroconversion* 33.9 (28.5, 40.6) 29.7 (25.6, 34.3) 30.6 (26.3, 35.9)
Date of incident AIDS*† 1993.9 (1992.3, 1995.9) 1992.7 (1991.3, 1994.6) 1993.0 (1991.4, 1994.9)
Years of follow-up* 6.2 (3.2, 13.5) 4.6 (2.1, 14.9) 5.1 (2.3, 14.4)
White, non-Hispanic (n) 84% (413) 74% (1,052) 77% (1465)
Cancer AIDS (n) 9% (40) 13% (188) 12% (228)
Non-cancer AIDS (n) 29% (132) 34% (484) 33% (616)




1992. 5=July 1, 1992
‡
Date of seroconversion imputed among seroprevalent men
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Table 2
The Effect of HAART Compared to Monotherapy/Combination Therapy on Progression to an AIDS-defining
Cancer among HIV-infected Men in the Multicenter AIDS Cohort Study, Accounting for other AIDS-defining








(Censors at date of
analysis)
Monotherapy/Combination Therapy, 1990–95
   Person-years 7422 4906 9172
   Cancer AIDS Events 197 197 197
   Non-cancer AIDS Events 522 --- ---
   AIDS-free deaths 58 --- ---
HAART, ≥ 1996
   Person-years 6780 6176 13 296
   Cancer AIDS Events 31 31 31
   Non-cancer AIDS Events 94 --- ---
   AIDS-free deaths 71 --- ---
Adjusted Rate Ratio (95% CI)* 0.165 (0.079, 0.340) 0.127 (0.079, 0.204) 0.146 (0.071, 0.299)
CI: confidence intervals
*
Adjusted for infection duration, age at seroconversion, race and cohort
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